Validation of the Functional Assessment of Cancer Therapy - Lymphoma (FACT-LYM) in Patients with Relapsed/Refractory Mantle Cell Lymphoma.

被引：0
|
作者：
Carter, Gebra Cuyun [1 ]
Liepa, Astra M. [1 ]
Zimmermann, Anna Hayden [2 ]
Morschhauser, Franck [3 ]
机构：
[1] Eli Lilly & Co, Global Hlth Outcomes, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Stat, Indianapolis, IN 46285 USA
[3] Ctr Hosp Univ, Lille, France
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：828 / 828
页数：1
相关论文
共 50 条
  • [1] MEASURING QUALITY OF LIFE (QOL) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA (NHL): THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-LYMPHOMA (FACT-LYM)
    Webster, K.
    Cashy, J.
    Cella, D.
    Kutikova, L.
    Gauthier, J.
    Liepa, A.
    Bowman, L.
    Gregory, S.
    QUALITY OF LIFE RESEARCH, 2005, 14 (09) : 2103 - 2103
  • [2] Salvage Treatment with Lenalidomide and Dexamethasone in Patients with Relapsed Refractory Mantle Cell Lymphoma.
    Zaja, Francesco
    De Luca, Stefano
    Vitolo, Umberto
    Orsucci, Lorella
    Levis, Alessandro
    Salvi, Flavia
    Gargantini, Livio
    Ravelli, Erika
    Tucci, Alessandra
    Bottelli, Chiara
    Balzarotti, Monica
    Santoro, Armando
    Brusamolino, Ercole
    Bonfichi, Maurizio
    Di Rocco, Alice
    Stelitano, Caterina
    Baldini, Luca
    Pileri, Stefano Aldo
    Volpetti, Stefano
    Ciccone, Giovannino
    Ferranti, Antonella
    Fanin, Renato
    BLOOD, 2009, 114 (22) : 683 - 683
  • [3] Development of a measure of health-related quality of life for non-Hodgkin's lymphoma clinical research: The functional assessment of cancer therapy - Lymphoma (FACT-Lym).
    Cella, D
    Webster, K
    Cashy, J
    Kutikova, L
    Burgess, MF
    Lin, BK
    Bowman, L
    Liepa, AM
    Gauthier, JE
    Gregory, SA
    Johnson, SA
    Cheson, BD
    BLOOD, 2005, 106 (11) : 222A - 222A
  • [4] Marked activity of, bortezomib, rituximab, and dexamethason in relapsed and refractory mantle cell lymphoma.
    Drach, Johannes
    Kaufmann, Hannes
    Pichelmayer, Oskar
    Sagaster, Verena
    Seidl, Sonja
    Chott, Andreas
    Zielinski, Christoph
    Raderer, Markus
    BLOOD, 2006, 108 (11) : 779A - 779A
  • [5] Phase II study of enzastaurin in the treatment of relapsed/refractory mantle cell lymphoma.
    Morschhausser, Frank
    Wolf, Martin
    Seymour, John
    Tilly, Herve
    Pfreundschuh, Michael
    Kluin-Nelemans, Hanneke
    Raemaekers, John
    van't Veer, Mars B.
    Milpied, Noel
    Cartron, Guillaume
    Pezzutto, Antonio
    Spencer, Andrew
    Darstein, Christelle
    Thornton, Donald
    Dreyling, Martin
    Reyes, Felix
    BLOOD, 2006, 108 (11) : 694A - 694A
  • [6] Bendamustine therapy for relapsed or refractory low grade B cell lymphoma and mantle cell lymphoma
    Yamada, Toshiki
    Shibata, Yuhei
    Nakamura, Nobuhiko
    Kitagawa, Jun-ichi
    Kanemura, Nobuhiro
    Kasahara, Senji
    Goto, Hideko
    Fukuno, Kenji
    Sawada, Michio
    Tsurumi, Hisashi
    ANNALS OF ONCOLOGY, 2015, 26 : 109 - 109
  • [7] Copanlisib in patients with relapsed or refractory follicular lymphoma.
    Dreyling, Martin H.
    Santoro, Armando
    Leppa, Sirpa
    Demeter, Judit
    Follows, George
    Lenz, Georg
    Kim, Won Seog
    Mollica, Luigina
    Nagler, Arnon
    Diong, Colin Phipps
    Provencio, Mariano
    Stevens, Don A.
    Trevarthen, David
    Magagnoli, Massimo
    Cupit, Lisa
    Yin, Shuxin
    Hiemeyer, Florian
    -Vargas, Jose E. Garcia
    Childs, Barrett H.
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Temsirolimus In Relapsed and/or Refractory Mantle Cell Lymphoma
    Hoy, Sheridan M.
    McKeage, Kate
    DRUGS, 2010, 70 (14) : 1819 - 1829
  • [9] Management of relapsed/refractory mantle cell lymphoma
    Alzahrani, Musa
    Villa, Diego
    LEUKEMIA & LYMPHOMA, 2024, 65 (08) : 1044 - 1054
  • [10] TemsirolimusIn Relapsed and/or Refractory Mantle Cell Lymphoma
    Sheridan M. Hoy
    Kate McKeage
    Drugs, 2010, 70 : 1819 - 1829
12345